☆ 4.1 Article

Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+breast cancer treatment in Saudi Arabia: simulation study

JOURNAL OF MEDICAL ECONOMICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Pharmacology & Pharmacy

An Institutional Guide for Formulary Decisions of Biosimilars

Sherin Ismail et al.

Summary: Biologics have revolutionized the treatment of chronic diseases, but they also come with a high cost. Fortunately, biosimilars offer a more affordable alternative as they are highly similar to the original biologics. To ensure the successful integration of biosimilars into hospital formularies, institutions must carefully evaluate key factors such as regulatory approval, interchangeability, manufacturing, and pharmacoeconomic evaluations. This institutional guide aims to provide insights for informed formulary decisions.

HOSPITAL PHARMACY (2023)

添加到收藏夹

Article Biology

Implementation of Next-Generation Sequencing in Saudi Arabia for HER2-Positive Breast Cancer

Rami Nassir et al.

Summary: This study investigated the genetic mutations and clinicopathological aspects of HER2 positive breast cancer patients in Saudi Arabia. The results showed that HER2 positive patients were significantly associated with c-MET, c-KIT, and PIK3CA. Mutations in other genes were also detected, and tumor size, grade, stage, and nodal status were found to be correlated with HER2 expression.

SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

Real-World Impact of Switching From Insulin Glargine (Lantus®) to Basaglar® and Potential Cost Saving in a Large Public Healthcare System in Saudi Arabia

Yazed AlRuthia et al.

Summary: This study aimed to examine the clinical and financial impact of switching from Lantus (R) to Basaglar (R). The results showed that switching to Basaglar (R) could lead to significant cost savings, but the differences in daily insulin units and acquisition prices should be considered.

FRONTIERS IN PUBLIC HEALTH (2022)

添加到收藏夹

Article Medicine, General & Internal

Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products

Thomas J. Moore et al.

Summary: This study examined the approval process of biosimilar biologic products by the US FDA and found that most comparative efficacy trials supporting the approval appeared to be as rigorous as pivotal trials for new molecular entities. Biosimilar approval requirements included animal studies and comparative efficacy clinical trials.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA

Ioana Gherghescu et al.

Summary: Biosimilar medicines have expanded the biotherapeutic market, with faster development and more approvals in the European market compared to the US market. Adalimumab biosimilars serve as a case study in this research.

PHARMACEUTICS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Incidence trends of breast cancer in Saudi Arabia: A joinpoint regression analysis (2004-2016)

Salman M. Albeshan et al.

Summary: The study reported an increasing trend in breast cancer cases among Saudi females from 2004 to 2016, with encouraging outcomes including a shift towards older age at diagnosis and an increased proportion of early-stage diagnoses. Higher annual percent changes were observed in smaller regions, emphasizing the need for region-based studies.

JOURNAL OF KING SAUD UNIVERSITY SCIENCE (2021)

添加到收藏夹

Article Biology

Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis

Shruti Rastogi et al.

Summary: The study found that filgrastim was effective and safe in reducing febrile neutropenia and related complications compared to placebo/no treatment, with no significant difference noted between pegfilgrastim and filgrastim in terms of efficacy and safety. Additionally, there was no statistically significant difference in the duration of severe neutropenia between filgrastim and biosimilar filgrastim.

BIOLOGY-BASEL (2021)

添加到收藏夹

Article Economics

Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer

Ali McBride et al.

Summary: The study shows that biosimilar intravenous trastuzumab-dkst is more cost-efficient compared to reference intravenous trastuzumab-IV and subcutaneous trastuzumab-SC in metastatic breast cancer patients, providing more patients with budget-neutral treatment options.

JOURNAL OF MEDICAL ECONOMICS (2021)

添加到收藏夹

Article Health Care Sciences & Services

The Economic Burden Associated with the Management of Different Stages of Breast Cancer: A Retrospective Cost of Illness Analysis in Saudi Arabia

Ahmed Alghamdi et al.

Summary: Breast cancer management in Saudi Arabia poses a substantial economic burden, with treatment costs varying significantly across different disease stages. Medication expenses are the primary driver of total healthcare spending, with targeted therapy drugs accounting for the majority of medication costs.

HEALTHCARE (2021)

添加到收藏夹

Article Economics

Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment

Ali McBride et al.

Summary: The study simulated cost-savings from converting from pegfilgrastim-OBI to pegfilgrastim-jmdb and evaluated the economic impact of FN-related hospitalization costs due to pegfilgrastim-OBI failure. The results showed significant cost-savings from the conversion, which could be used to provide additional treatment for more patients.

JOURNAL OF MEDICAL ECONOMICS (2021)

添加到收藏夹

Article Economics

Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim

Ali McBride et al.

JOURNAL OF MEDICAL ECONOMICS (2020)

添加到收藏夹

Article Economics

Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv

Karen MacDonald et al.

JOURNAL OF MEDICAL ECONOMICS (2020)

添加到收藏夹

Article Oncology

Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence

Salvatore Bellinvia et al.

BIODRUGS (2019)

添加到收藏夹

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Pharmacology & Pharmacy

First GCC stakeholder meeting on approval process, interchange-ability/substitution and safety of biosimilars 2017 - Report

Gianluca Trifiro et al.

GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2018)

添加到收藏夹

Article Oncology

Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz

Ali McBride et al.

FUTURE ONCOLOGY (2017)

添加到收藏夹

Review Endocrinology & Metabolism

The rise of biosimilars: How they got here and where they are going

Dhiren Patel et al.

METABOLISM-CLINICAL AND EXPERIMENTAL (2017)

添加到收藏夹

Article Economics

Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia

Ali McBride et al.

JOURNAL OF MEDICAL ECONOMICS (2017)

添加到收藏夹

Article Oncology

Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)

Pere Gascon et al.

SUPPORTIVE CARE IN CANCER (2016)

添加到收藏夹

Article Oncology

Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)

M. Aapro et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Pharmacology & Pharmacy

Potential Cost Savings From Chemotherapy-Induced Febrile Neutropenia With Biosimilar Filgrastim and Expanded Access to Targeted Antineoplastic Treatment Across the European Union G5 Countries: A Simulation Study

Diana Sun et al.

CLINICAL THERAPEUTICS (2015)

添加到收藏夹

Article Oncology

Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries

Ivo Abraham et al.

FUTURE ONCOLOGY (2014)

添加到收藏夹

Review Oncology

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential

Parvin F. Peddi et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)

添加到收藏夹

Review Pharmacology & Pharmacy

Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors

Ivo Abraham et al.

EXPERT OPINION ON DRUG SAFETY (2013)

添加到收藏夹

Review Oncology

Clinical experience with ZarzioA® in Europe: what have we learned?

Pere Gascon et al.

SUPPORTIVE CARE IN CANCER (2013)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Biosimilars in 3D Definition, development and differentiation

Ivo Abraham et al.

BIOENGINEERED (2013)

添加到收藏夹

Article Oncology

Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer

Matti Aapro et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2012)

添加到收藏夹

Article Oncology

Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia

Matti Aapro et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2011)

添加到收藏夹

Article Oncology

Development of a new G-CSF product based on biosimilarity assessment

P. Gascon et al.

ANNALS OF ONCOLOGY (2010)

添加到收藏夹

Article Pharmacology & Pharmacy

Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?

D Weycker et al.

ANNALS OF PHARMACOTHERAPY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.